Pluristem Radiation Exposure Drug Cleared for Emergency Use

The FDA cleared Pluristem’s PLX-R18 therapy for treating radiation exposure in an emergency situation.

Pluristem is still seeking full approval of the drug based on the results of a Phase 3 clinical trial, and is in discussions with the FDA and several other agencies to organize a study. It previously completed a mid-stage study sponsored by the NIH’s National Institute of Allergy and Infectious Diseases.

The Department of Defense is also studying the drug for its potential to support service members within the first 24 hours of radiation exposure.